Eli Lilly is trading at ARS 34,960.00, up 4.17%, with healthcare-sector strength offering a possible tailwind.
- Healthcare rose 1.64% during the regular session, supported by UnitedHealth’s earnings beat and raised outlook.
- No clear company-specific announcement directly explains the October 14 move. Recent exploratory Taltz–Zepbound biomarker data has not been established as its cause.
- Major U.S. indexes were mixed or lower.